医疗科技股票表现 - 医疗科技股票在过去两年表现不佳，但通过股息支付得到部分抵消[1] - 许多医疗科技股票目前交易于价值水平，预计未来两年增长将保持稳定[2] - 医疗科技股票的增长受到COVID的影响，市场缺乏稳定的推动力[3] - 医疗科技公司预计未来两年将保持稳定增长，受益于创新、后COVID的正常化、全球人口增长、新兴市场经济发展和现有市场的渗透[4]

A near 2.0% post-earnings decline in Abbott Laboratories (NYSE: ABT) warrants an investment in the health care giant, says Jim Cramer. Cramer’s bullish view on Abbott stock Copy link to section His Charitable Trust bought 275 shares of the medical devices company at $112 each on Monday. Cramer is confident that the weight-loss drugs are not a threat for this Chicago-based maker of FreeStyle Libre (continuous glucose monitoring system). The Mad Money host is bullish on Abbott stock also for the nutrition bus ...

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this maker of infant formula, medical devices and drugs have returned +1.8% over the past month versus the Zacks S&P 500 composite's +2.5% change. The Zacks Medical - Products industry, to which Abbott belongs, has gained 1.6% over this period. Now the key question is: Where could the stock be headed in the near te ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Abbott (ABT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Abbott is a member of our Medical group, which includes 1075 different companies and currently sits at ...

JHVEPhoto Since I initiated coverage on October 20, 2023, Abbott Laboratories' (NYSE:ABT) stock price has risen by 16.6%, compared to the index return of 14.2%. I highlighted their robust and innovative product pipeline in the introductory article. I believe the company is successfully overcoming challenges related to the COVID-19 pandemic, and I reiterate a 'Strong Buy' rating with a fair value of $115 per share. Recent Result and FY24 Outlook In Q4 FY23, Abbott Laboratories achieved 2.1% organic revenue g ...

Abbott Laboratories的股价表现 - Abbott Laboratories的股价在发布实质性业绩后急剧下跌，为投资者提供了买入机会[1] - Abbott Laboratories的股价在过去几个季度一直处于区间内，但有突破的迹象[6] - 市场在发布后急剧下跌，但在30日移动平均线处找到支撑，预计股价将反弹[7] Abbott Laboratories的业务表现 - 公司正在经历COVID-19影响多年后回归核心有机增长的转变[1] - Abbott Laboratories的核心业务稳健增长，预计未来几个季度系统范围增长将加速[2] - Abbott在MedTech领域表现强劲，核心非COVID业务有机收入增长11%[3] - MedTech预计将保持稳健增长，受到手术和服务需求的支撑[4] Abbott Laboratories的未来展望 - Abbott的指导方针支持健康的股息，预计核心业务收入将保持高个位数至低两位数增长[5] - 分析师们正在提高他们的价格目标，可能推动股价突破交易范围[1] - 分析师们纷纷提高Abbott的价格目标，预计股价有望上涨[6]

o « Liberta RC™ deep brain stimulation (DBS) system, recently approved by the U.S. FDA, features NeuroSphere™ Virtual Clinic, which allows for remote programming of the system System offers the longest time between charges of any DBS technology on the market, allowing people with movement disorders to recharge the device only 10 times a year2* ABBOTT PARK, Ill., Jan. 25, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it received approval from the U.S. Food and Drug Administration (FDA) to laun ...

Less than two years after a headline-grabbing shutdown of a baby formula plant in Michigan, Abbott ... [+] Laboratories has "reclaimed its previous market-leading position," the company said Jan. 24, 2024. The Abbott manufacturing facility in Sturgis, Michigan, on May 13, 2022. (Photo by JEFF KOWALSKY / AFP) (Photo by JEFF KOWALSKY/AFP via Getty Images) AFP via Getty Images Less than two years after a headline-grabbing shutdown of a baby formula plant in Michigan that fueled a national crisis, Abbott Labora ...

业绩总结 - 2023年销售和盈利增长超出预期，销售和盈利增长超过11%[18] - 第四季度基础业务有机销售增长11%[32] - 预测2024年总基础业务有机销售增长率为8%至10%[34] - 公司的核心业务在过去几年实现了双位数增长[49] - 预计今年的每股收益将实现两位数增长[50] 用户数据 - 婴儿营养产品销售增长14%，成人营养产品销售额超过40亿美元，增长13.5%[22] - 全球销售超过53亿美元，Libre成为历史上最成功的医疗器械之一[29] - 公司在2023年第四季度取得了强劲增长，美国市场增长了32%[69] - Libre在美国处方药市场占有率高，七成新处方选择Libre[71] 未来展望 - 2024年预计销售增长（不包括COVID测试）将达到8%至10%，调整后每股收益预计为4.50至4.70美元[21] - 2023年表现出色，预测2024年将继续保持强劲增长[30] - 公司预计这五个产品将增长50%[86] - 2024年预计公司的顶级增长[108] 新产品和新技术研发 - Alinity继续推动高合同续约率和竞争胜率，FDA批准了新的实验室自动化系统[26] - 公司预计新的PFA系统在美国市场推出后会受到一定程度的接受和使用，但可能会面临一些挑战[64] - 公司正在开发新的Alinity系统，以抢占目前未竞争的诊断市场领域[88] - 公司还有其他产品在研发和推出，包括Lingo、TBI测试、GLP-1用户的营养饮料和PFA解决方案Volt[86] 市场扩张和并购 - 公司拥有强大的资本实力，有能力进行大规模并购交易，但会非常谨慎选择，不会仅仅为了扩大营收而进行收购[96][97][98][99] 其他新策略 - 公司的运营利润率已经恢复到疫情前的水平，并且预计在未来会有更多的增长[53] - 公司计划在今年实现毛利率的大幅提升，预计将增加约75个基点[56] - 公司认为医疗设备市场的增长是正常的，没有出现异常的追赶情况，而是技术的采用率在增加[102][103][105]

财务表现 - Abbott Laboratories (ABT) 第四季度2023年调整后每股收益为$1.19，与Zacks Consensus Estimate一致[1] - 第四季度全球销售额为102.4亿美元，同比增长1.5%[4] - Established Pharmaceuticals产品销售额同比增长0.5%（有机基础上增长8.8%）[8] - Medical Devices部门销售额同比增长17.5%（有机基础上增长15.4%）[10] - Nutrition部门销售额同比增长12.2%（有机基础上增长13.9%）[14] - Diagnostics部门销售额同比下降22.7%（有机基础上下降22.3%）[16] - 第四季度毛利润同比增长3.4%，毛利率扩大103个基点至55.5%[18] - SG&A费用同比下降8.4%，研发费用同比下降3.4%[19] - 全年2024年调整后每股收益预计在4.50-4.70美元之间[20] 市场表现 - Abbott在2023年继续在美国婴儿配方市场中重新夺回市场份额的领先地位[23]